Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma

NCT01874171 is registered in ClinicalTrials.gov with University of Warwick as lead sponsor.

NCT NCT01874171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01874171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
University of Warwick
Phase
Phase 3
Overall status
Unknown status
Start date
November 15, 2012
Completion date
February 28, 2019
Enrollment
334 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal squamous cell carcinoma